|
|
|
|
Gilead Fourth Quarter Profit Rises 43% on Atripla Sales
FOSTER CITY, Calif.(AP) ' Gilead Sciences Inc. said Tuesday its profit climbed 43 percent in the fourth quarter due to rising sales of its three-in-one HIV drug Atripla. The company said sales of Atripla, which was approved in the U.S. in July 2006,...
|
|
|
Gilead 4Q Profit Rises 43 Percent on Atripla Sales
FOSTER CITY, Calif.--Gilead Sciences Inc.said Tuesday its profit climbed 43 percent in the fourth quarter due to rising sales of its three-in-one HIV drug Atripla. The company said sales of Atripla, which was approved in the U.S. in July 2006, jumped 50...
|
|
|
Gilead Sciences' 3-in-1 HIV treatment became its top drug in 4Q as Atripla sales rose 50 pct
FOSTER CITY, CALIF.Gilead Sciences Inc. said Tuesday its profit climbed 43 percent in the fourth quarter due to rising sales of its three-in-one HIV drug Atripla. The company said sales of Atripla, which was approved in the U.S. in July 2006, jumped 50...
|
|
|
Gilead 4Q profit rises 43 percent on Atripla sales
FOSTER CITY, Calif.-- Gilead Sciences Inc. said Tuesday its profit climbed 43 percent in the fourth quarter due to rising sales of its three-in-one HIV drug Atripla. The company said sales of Atripla, which was approved in the U.S. in July 2006, jumped...
|
|
|
Gilead 4Q profit rises 43 percent on Atripla sales
FOSTER CITY, Calif.(AP) -- Gilead Sciences Inc. said Tuesday its profit climbed 43 percent in the fourth quarter due to rising sales of its three-in-one HIV drug Atripla.The company said sales of Atripla, which was approved in the U.S. in July 2006,...
|
|
|
Ranexa (ranolazine extended-release tablets)
_ Ranexa (ranolazine extended-release tablets).
|
|
|
TargetCast tcm Acquires Triumph360
Subscribe to Pharmaceutical News on Ulitzer: Email Alerts Weekly Newsletters Get Pharmaceutical News on Ulitzer: Homepage Mobile RSS Facebook Twitter LinkedIn Pharmaceuticals Authors: Don Nelson Related Topics: CEOs in Technology, CIO/CTO Update, SEO Journal,...
|
